Krutsinger Dustin, Pezzulo Alejandro, Blevins Amy E, Reed Robert M, Voigt Michael D, Eberlein Michael
Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.
Division of Pulmonary, Critical Care and Occupational Medicine, University of Iowa, Iowa City, IA, USA.
Clin Transplant. 2017 May;31(5). doi: 10.1111/ctr.12957. Epub 2017 Apr 7.
Idiopathic hyperammonemia syndrome (IHS) is an uncommon, often deadly complication of solid organ transplantation. IHS cases in solid organ transplantation seem to occur predominantly in lung transplant (LTx) recipients. However, to the best of our knowledge, the occurrence of IHS has not been systematically evaluated. We set out to identify all reported cases of IHS following nonliver solid organ transplantations.
Retrospective review of our institutional experience and systematic review of the literature.
At our institution six cases (of 844 nonliver solid organ transplants) of IHS were identified: five occurred following LTx (incidence 3.9% [lung] vs 0.1% [nonlung], P=.004). In the systematic review, 16 studies met inclusion criteria, reporting on 32 cases of IHS. The majority of IHS cases in the literature (81%) were LTx-recipients. The average peak reported ammonia level was 1039 μmol/L occurring on average 14.7 days post-transplant. Mortality in previously reported IHS cases was 69%. A single-center experience suggested that, in addition to standard treatment for hyperammonemia, early initiation of high intensity hemodialysis to remove ammonia was associated with increased survival. In the systematic review, mortality was 40% (four of 10) with intermittent hemodialysis, 75% (nine of 12) with continuous veno-venous hemodialysis, and 100% in six subjects that did not receive renal replacement to remove ammonia. Three reports identified infection with urease producing organisms as a possible etiology of IHS.
IHS is a rare but often fatal complication that primarily affects lung transplant recipients within the first 30 days.
特发性高氨血症综合征(IHS)是实体器官移植中一种罕见且常致命的并发症。实体器官移植中的IHS病例似乎主要发生在肺移植(LTx)受者中。然而,据我们所知,IHS的发生尚未得到系统评估。我们着手识别非肝脏实体器官移植后所有报告的IHS病例。
回顾我们机构的经验并对文献进行系统回顾。
在我们机构,844例非肝脏实体器官移植中有6例IHS病例被识别:5例发生在肺移植后(发生率3.9%[肺]对0.1%[非肺],P = 0.004)。在系统回顾中,16项研究符合纳入标准,报告了32例IHS病例。文献中大多数IHS病例(81%)是肺移植受者。报告的氨水平平均峰值为1039μmol/L,平均发生在移植后14.7天。既往报告的IHS病例死亡率为69%。一项单中心经验表明,除了高氨血症的标准治疗外,早期开始高强度血液透析以清除氨与生存率增加相关。在系统回顾中,间歇性血液透析的死亡率为40%(10例中的4例),持续性静脉 - 静脉血液透析的死亡率为75%(12例中的9例),6例未接受肾脏替代治疗以清除氨的患者死亡率为100%。三项报告确定感染产脲酶微生物可能是IHS的病因。
IHS是一种罕见但常致命的并发症,主要影响肺移植受者,发生在移植后的前30天内。